1553 EARLY IHDOMETHACIN (IND) DOES NOT PREVENT BRONCHOPULMONARY DYSPLASIA (BPD) IN A RANDOMIZED CLINICAL TRIAL

Abstract

Thirty infants < 1500 g at birth on IPPB or CPAP by 12 hours were entered in a randomized double blind controlled trial to test the efficacy of IND in preventing BPD. 15 treated infants received IND at 12, 24 and 36 hours of age while 15 control infants received normal saline at these times. The groups were similar for birth weight, gestational age and sex.Although there was a 65% probability of detecting a 50% reduction in BPD, there was in fact no difference in the incidence of BPD between the two groups. The incidence of IRDS and IVH was similar in the two groups. There was a tendency towards reduced incidence of symptomatic PDA (SPDA) in the IND group but it did not reach significance. There were no cases of NEC in either group and the incidence of pneumothorax and RLF was similar. Length of stay, length of ventilator support and length of oxygen therapy did not differ between the two groups.IND may reduce the incidence of SPDA. However, when given within 12 hr of birth, IND does not reduce the incidence or severity of BPD, or the need for ventilation or oxygen.